LOS ANGELES – But in the United States, only about 1% of eligible patients with diabetes undergo the procedure.
Type 2 diabetes patients using SGLT2 inhibitors had significantly lower rates of gout than did those taking GLP1 agonists.
Nonsurgical interventions via lifestyle modifications and pharmacotherapy have not demonstrated success.
WASHINGTON – Dr. Robert E. Ratner and Dr. Kim Boggess expound on the evidence base for using metformin and give their takes on postpartum clinical...
"This assessment may be excessively pessimistic; indeed, we hope that is the case," the panel said.
Metabolic surgery was associated with a significantly lower cumulative incidence of myocardial infarction, ischemic stroke, and mortality than...
Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy.
Cascade of diabetes care in the United States has not improved since 2005.
It is the first glucagon therapy approved for this indication that is administrable without an injection.
Each percentage increase in hemoglobin level was associated with a 7% increase in fracture risk.
The price tags on these drugs are the biggest barrier to their use.
Nearly half of participants in an exercise program achieved at least the scheduled activity target of 150 minutes of physical activity per week....
SAN FRANCISCO – Vitamin D supplementation failed to significantly reduce the risk of progression from prediabetes to...
LOS ANGELES – Yehuda Handelsman, MD, and Paul S. Jellinger, MD, summarized some of the key takeaways from this year’...
Serious complications and death are likely if Fournier gangrene is not recognized.
Evaluation of risk factors for short- and long-term fracture risk may help improve risk stratification in patients with type 2 diabetes.
PHILADELPHIA – More head-to-head trials of treatments for neuropathic pain are needed.
Canagliflozin is currently indicated for patients with type 2 diabetes but may soon help treat those who also have chronic kidney disease.
SGLT2 inhibitors and GLP-1 RAs have different effects on cardiovascular and kidney disease outcomes in patients with type 2 diabetes.
Once-weekly treatment with the GLP-1 RA semaglutide helped most patients with type 2 diabetes on SGLT2 inhibitors meet their glycemic targets and...
